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Background: The treatment strategy for gastric diffuse large cell lymphoma (DLBCL) has not been standardized in
such as to the cycles of chemotherapy, dose of radiation, or necessity for the surgery. Although the results of CHOP
or R-CHOP treatments have demonstrated the good prognosis, the treatments have been controversial in many
cases.
Methods: We retrospectively analyzed 40 gastric DLBCL patients receiving chemotherapy with or without radiation
in our institute. Those in stages II-IV were treated with six cycles of R-CHOP without radiation; for those in stage I,
we administered three cycles of R-CHOP with radiation.
Results: The three-year overall survival (OS) and progression-free survival (PFS) rates were 95.2 and 91.8%,
respectively. Those in stage I obtained 100% of OS. The radiation dose prescribed was 30.6 Gy for CR cases and 39.6
to 40 Gy for PR after chemotherapy. Although survival rates tended to correlate with staging groups or
age-adjusted IPI classifications, multivariate statistical analysis did not show clear differences. All 14 patients with
initial bleeding were successfully managed without surgery during treatment.
Conclusion: R-CHOP therapy was very effective for gastric DLBCL. It may be not necessary to use more than
30.6 Gy of radiotherapy in the highly chemo-sensitive cases. Less toxic treatments should be made available to
gastric DLBCL patients.
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Primary gastric diffuse large B cell lymphoma (DLBCL)
is a relatively common disease in gastric lymphoma as
well as gastric marginal zone B cell lymphoma (MALT).
In many previous reports, the prognosis for gastric
lymphoma was considered good; however, these reports
involved MALT, indolent lymphoma, and DLBCL cases
[1,2]. Treatments were varied and included surgical re-
section, radiotherapy, antibiotics against helicobacter
pyroli, and chemotherapy [3]. Reports focusing only on
primary gastric DLBCL are very few, and the treatment* Correspondence: khatake@jfcr.or.jp
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reproduction in any medium, provided the orstrategy has not been stabilized and individualized across
institutions. Recently, it has been known that rituximab
combined CHOP (R-CHOP) has been shown to be very
effective for DLBCL, remarkably improving overall sur-
vival and progression free-survival [4]. For localized
DLBCL, radiation following limited cycles of R-CHOP
led to good prognosis [5-7]. In the Southwest Oncology
Group Study (SWOG) 0014 study, RCHOP with radio-
therapy for early-stage gastric DLBCL demonstrated a
good prognosis [8]. Ferrucci summarized in his review
using three to four cycles of R-CHOP followed by
involved field radiotherapy in early-stage of DLBCL and
using six to eight cycles of R-CHOP alone in advanced-
stage patients [9].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with primary gastric DLBCL without resection and
examined the possibility of using less-toxic treatment.
Patients and methods
Patient eligibility and diagnosis
We retrospectively analyzed 40 patients diagnosed with
gastric DLBCL in our institute between November 2003
and October 2008. The tissue specimens were obtained
from the biopsies of gastric tumors using upper endos-
copy and were diagnosed using immunohistochemical
staining and flowcytometry by expert hematological
pathologists. Disease stages were based on the Lugano
classification [10], using computed tomography (CT),
ultra-sound examination (US), positron emission tomog-
raphy with or without CT (PET/CT), and bone marrow
aspiration and biopsy. In the cases with other invasions
in nodal or extra nodal sites, if the cases had predomin-
ant lesions in stomach, we diagnosed as primary gastric
lymphoma [11]. Cases with gastric mass exceeding more
7 cm were classified as bulky disease.
Treatment and evaluation
Treatment strategy was classified dependent on stage.
Patients with stage I but not bulky disease were treated
with three cycles of R-CHOP; eight doses of rituximab
(375 mg/m2 weekly) and three cycles of CHOP (Cyclo-
phosphamide 750 mg/m2, day 1; vincristine 1.4 mg/m2,
day 1; doxorubicin 50 mg/m2, day 1; and Prednisolone
60 mg/m2, days 1-5; tri-weekly) followed by involved
field radiotherapy. Patients with stage II-IV were treated
with six cycles of R-CHOP (eight cycles of weekly rituxi-
mab and six cycles of CHOP) without radiotherapy.
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Figure 1 The schema of treatment of gastric DLBCL in our study.with six cycles of R-CHOP followed by radiotherapy.
CHOP doses were decreased to 80 percent in patients
older than 75 years old, and in the patients experienced
with grade 4-hematological toxicity, and/or grade 3 or
more grade of non-hematological toxicity. G-CSF sup-
ports were administered to patients older than 70 and to
patients who had FN in previous cycles. Basically, all
patients received an endoscopy after the first cycle of
chemotherapy and after completing the treatment. PET
scans were performed after 3 cycles of chemotherapy in
the limited stage. Response to total treatment was evalu-
ated using CT scans four weeks after and using PET/CT
scans and endoscopy six weeks after the last treatments.
Radiation therapy
Three-dimensional conformal radiation planning (Eclipse,
Varian Medical Systems, Palo Alto, CA.) based on CT
with/without respiratory gating was required for all
patients for whom radiation therapy was indicated. The
clinical target volume of radiotherapy encompassed the
entire stomach and involved the perigastric or abdominal
lymph node regions if nodal lesions were present. We
also added an appropriate margin to the clinical target
volume taking into account respiratory gastric move-
ments. The prescribed dose of radiotherapy was 30.6 Gy
in 17 fractionations over 3.5 weeks for CR cases and
39.6 Gy in 23 fractionations over 4.5 weeks or 40 Gy in
PR case (Figure 1). Radiation therapy was delivered with
a 10 or 15 MV photon beam linear acceralator (CL2100,
Varian Medical Systems, Palo Alto, CA.).
Ethics of treatment design
Our treatment design was based on NCCN guidelines
for diffuse large lymphoma [12]. Radiation doses wereL
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Table 1 Patient characteristics
Patient characteristics No. of patients








I (Ix) 15 (2) (37.5%)
II II1 8 (20.0%)
II2 3 (7.5%)
IIE 2 (5.0%)









3 cycles R-CHOP + RT (30 Gy) 11 (27.5%)
6 cycles R-CHOP 21 (52.5%)
6 cycles R-CHOP + RT (30 Gy) 3 (7.5%)
drop out 5 (12.5%)
*involved site; liver (4) lung, pleural effusion (5) mediastitial LNs (3).
Abbrebiations; GC; germinal center type, RT; radiotherapy.
Mishima et al. Experimental Hematology & Oncology 2012, 1:30 Page 3 of 6
http://www.ehoonline.org/content/1/1/30selected according to NCCN guidelines in which recom-
mended dose were 30 Gy in CR cases and 40 Gy in PR
cases. Decisions on initial treatment for all patients with
gastric bleeding or having risk of perforation were dis-
cussed by a lymphoma cancer board comparing hematolo-
gists, surgeons, radiologists, and radiation oncologists.
Follow-up and statistical analysis
All patients were followed by medical oncologists and by
radiation oncologists every three months for two years,
then every six months for the next three years, with
repeated CT scans and/or endoscopy.
Statistical analyses of progression-free survival (PFS) and
overall survival (OS) were calculated using Kaplan-Meier
estimators. Categories were compared by means of a log-
rank test. As risk factors, we included age-adjusted (aa)
IPI, disease stage, GC vs non-GC subtype, hemoglobin
level (Hb< 12.0 g/dl), stage, bleeding, CRP level, be-ta 2
microglobulin, and IL-2 as risk factors. Taking stage-risk
in IPI score into consideration, we estimated Lugano-stage
IV as high risk and I, II as low risk. Using Cox propor-
tional hazards regression analysis, univariate and multi-
variate analysis were performed on these risk factors.
Results
Patient characteristics and prognostic factors
Patient characteristics are shown in Table 1. In total, 40
patients were analyzed in this study. The median age was
65.5 years (30-79 years old), and 21 patients (52.5%) were
male. For aa IPI, low was 23, low intermediate was 8, high
intermediate was 3, and high was 6 cases. The patients
with Stage IV involved extensive lesions such as lung, liver,
and mediastitial lymph nods. GC and non-GC types were
23 (75%) and 10 (25%), respectively. For the level of
hemoglobin (Hb), lower than 12 g/dl was 11, and bleeding
or deep ulcer cases at diagnosis were fourteen. Thirty-five
of 40 patients completed the planned treatment.
Treatment feasibility
Fifteen patients were stage I (27.5%), including two with
bulky disease, and 11 patients received three cycles of R-
CHOP (rituximab was 8 cycles, weekly), followed by ra-
diation. The two with bulky disease received 6 cycles of
R-CHOP and radiation. Two patients received only
3 cycles of RCHOP alone because of their complications
and concomitant disorders.
Twenty-one patients (72.5%) were stage II and IV (stage
II was 13, IV was 12) and all of them were treated with
6 cycles of RCHOP (rituximab was 8 cycles, weekly). One
case of stage II with bulky disease received 6 cycles of R-
CHOP with consolidative radiation therapy.
Of the patients receiving radiotherapy, nine patients
with CR after chemotherapy received 30.6 Gy, and five
patients with PR received 39.6 Gy or 40 Gy.In the fourteen patients with initial presentation of
bleeding from ulcerative lymphoma lesions, there were
none with repeated gastric bleeding or perforation after
chemotherapy.Initial treatment response and survival
The average duration of observation duration was
42.5 months. The complete remission (CR) rate overall
was 87.5% (35/40), and in only one patient did disease
progress (PD) during R-CHOP treatment. One patient
relapsed after obtaining CR. The relapse sites were para-
aortic and peritoneal lymph nodes. There was no gastric
invasion. Three-year OS and PFS rates of the study
population were 95.2% and 91.8%, respectively (Figure 2).
According to the prognostic factors, three-year-OS was
100% and 83.3% in stages I-II and IV, respectively. And
that of PFS was 100%, 92.3%, and 79.5% in stages I, II,
and IV, respectively (Figure 3). Otherwise, three-year OS
dependent on aa-IPI was 100% and 68.6% in 1-3 and 4,
respectively. That of PFS was 87.5% and 53.3% in aa-IPI
1-3 and 4, respectively (Figure 4). According to the
(A) (B)
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Figure 2 Kaplan-Meier curve of overall survival (A) and progression free survival (B) for all patients.
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and 100% in all three cycles R-CHOP with radiation,
91.3% and 87.0% in six cycles R-CHOP, 100% and 100%
in six cycles R-CHOP with radiation, respectively.
Univariate statistical analysis of IL-2, be-ta 2 microglo-
bulin, CRP, GC or non-GC subtype did not show signifi-
cant differences in survival. However, there were
marginally significant differences between stage I-II and
IV (OS; p= 0.0328, PFS; p= 0.0273) (Figure 3) and be-
tween aa-IPI 1-3 and 4 (OS; p= 0.004, PFS; p= 0.0238)
(Figure 4), These survival differences were not significant
in multivariate analysis (data not shown).
Treatment toxicity
Adverse events greater than grade3 are shown in Table 2.
The main adverse events were grade 4 neutropenia 40.0%
and febrile neutropenia 17.5%. Those who dropped out
from these regimens did so because of psychosis, colitis,
myelosuppression, intestitial pneumonia, and liver dam-
age, one case for each of these. Both cases with psychosis
and colitis were 79 years old, both were stages IV, and they
had severe performance status at the diagnosis. There was

























stageI,II, 3 year OS100% 
stage IV, 3 year OS 83.3%
Figure 3 Overall survival (A) and progression free survival (B) in classgrade3 liver toxicity was induced in the first cycle of R-
CHOP and had no liver invasion. The case with severe
myelosupression had no bone marrow invasion but was
stage IV. One patient with stage IIE had interstitial pneu-
monia due to Pneumocystis Jiroveci after 5 cycles of R-
CHOP. No acute and delayed radiation-related toxicities,
such as chronic gastric ulcer, liver dysfunction, and renal
insufficiency, graded 3 or higher, were documented during
the observation period.Discussion
R-CHOP has been recognized as standard therapy of
DLBCL. In Wohrer’s report, R-CHOP for the early stage
of gastric DLBCL resulted in 87% CR, with 12 of 15
patients alive at 15 months after chemotherapy [13]. Al-
though our study was small sample size, all the stage I
patients obtained CR, with both OS and PFS at 100%,
and also stage II-IV patients obtained long survival. We
should consider cases with bleeding and/or potential
bleeding from deep ulcerative lesions, always paying at-
tention to the possibility of repeated bleeding or perfor-
ation of stomach after chemotherapy. Although such(B)
p=0.0278
stageI,II, 3 year PFS 93.7% 


















































































IPI 1-3, 3 year OS 100% 
IPI 4,    3 year OS 68.6% IPI 1-3, 3 year PFS 87.5% 
IPI 4,    3 year PFS 53.3%
Figure 4 Overall survival (A) and progression free survival (B) in classified with aa-IPI 1-3 and 4.
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complete R-CHOP safely.
The dose of radiotherapy should be discussed. In the
SWOG0014 study, the dose of involved field radiation
was 40-46 Gy [6]. A Japanese multi-center phase II trial
reported using 40.5 Gy of radiation [14]. In another
phase II study, four cycles of CHOP with IFRT of 40 Gy
was adjusted to early stage of primary gastric DLBCL
[15]. The IELSG4 study compared chemotherapy only
without rituximab treatment versus chemotherapy with
involved field radiotherapy. In this study, cases were lim-
ited to stage I to stageIIE, and they evaluated after four
cycles of CHOP-like regimens. Then if the cases
obtained CR, they were randomized to an additional two
cycles of chemotherapy and 30 Gy involved field RT.
There were no significant differences in OS between theTable 2 Treatment result and adverse events
Treatment result No. of patients (total









Non-Hematological toxicity (grade3 and 4)
febrile neutropenia 7 (17.5%)





Abbrebiations; CR; complete remission, PD; progressive disease.two arms, though DFS was significantly better than
radiotherapy groups, and four cases (18%) relapsed in
the chemotherapy-alone group [16]. In our study, we
planned the dose of radiation as 30.6 Gy in CR cases
and 39.6-40 Gy in PR cases based on NCCN guidelines
for DLBCL [12] and there were no relapses. This con-
sensus was based on expert opinion that the volume and
dose of radiation therapy should be as minimimal as
possible because the gastric DLBCL is surrounded with
at-risk organs such as liver, kidneys and heart.
Radiation-induced acute toxicities such as nausea and
appetite loss and delayed toxicities such as gastric ulcer
and renal or liver dysfunction could be reduced by lower
dose of radiation. The risk of secondary malignancy
should be evaluated after 10 years following this treat-
ment. It is a very important point of treatment for gas-
tric DLBCL, although it is difficult to conduct a
randomized study specifically focusing on the doses of
radiation therapy, mainly because of patient accrual.
Furthermore, we administered eight doses of rituxi-
mab in the treatment, compared to four doses in the
SWOG0014 study [6]. To complete infusion of eight
cycles of rituximab during chemotherapy, we decided
on weekly administration of rituximab. The eight doses
of rituximab might have contributed to our good
results.
In this our present report, most patients dropping
chemotherapy were stage IV and high score of aa-IPI,
and their case were complicated by severe general condi-
tion at diagnosis. All patients who completed R-CHOP
with or without radiotherapy were able to obtain long
PFS and OS. We therefore recommend R-CHOP therapy
as a promising treatment for gastric lymphoma, carefully
selecting the dose of radiotherapy dependent on chemo-
sensitivity.Competing interests
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